> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Advisory Committee to Review Purdue Opioid Pain Drug
- URL: https://www.fdaweb.com/joint-advisory-committee-to-review-purdue-opioid-pain-drug/
- Published: 2017-08-16T12:00:00.000Z
- Updated: 2026-09-14T22:41:40.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139394

*Federal Register* notice: FDA has a announced a 9/14 joint meeting of its Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee. Panel member are scheduled to review a Purdue Pharma supplemental NDA new for Butrans (buprenorphine) transdermal system for use in pediatric patients aged seven through 16 years for managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Specifically, they will discuss the findings from a Butrans clinical study conducted in pediatric patients, and whether data support additional labeling. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-08-16/pdf/2017-17303.pdf?ref=fdaweb.com).